A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma (UNIK)
A Phase III, Randomized, Non-inferiority, Open-label, Comparative Study Between Foraseq® Inhalation Capsules, Eurofarma's Single Formoterol / Budesonide Inhalation Capsule and Single Alenia® Inhalation Capsule in Asthmatic Patients
Sponsor: Eurofarma Laboratorios S.A.
A PHASE3 clinical study on Asthma, this trial is completed. The trial is conducted by Eurofarma Laboratorios S.A. and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eurofarma Laboratorios S.A.
For direct contact, visit the study record on ClinicalTrials.gov .